Search Results | Blood | American Society of Hematology

1-20 of 68

2 3 4

Sort by

Sort Order Select

Journal Articles

A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study

Urvi A Shah, Daniel Alicea, Peter A. Adintori, Miranda Burge, Jenna Blaslov, Andriy Derkach, Sham Mailankody, Neha Korde, Carlyn Tan, Malin Hultcrantz, Sydney X. Lu, Dhwani Patel, Hani Hassoun, Anita D'Souza, Sergio A Giralt, Neil Iyengar, Ola Landgren, Marcel van den Brink, Alexander Lesokhin

Blood (2021) 138 (Supplement 1): 4759.

DOI: https://doi.org/10.1182/blood-2021-151049

Published: 2021

Journal Articles

Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures

Blood (2021) 138 (Supplement 1): 4762.

DOI: https://doi.org/10.1182/blood-2021-150684

Published: 2021

Journal Articles

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 827.

DOI: https://doi.org/10.1182/blood-2021-153204

Published: 2021

Journal Articles

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience

Blood (2021) 138 (Supplement 1): 1644.

DOI: https://doi.org/10.1182/blood-2021-153443

Published: 2021

Journal Articles

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Blood (2021) 138 (Supplement 1): 3271.

DOI: https://doi.org/10.1182/blood-2021-145927

Published: 2021

Journal Articles

Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd)

Blood (2021) 138 (Supplement 1): 325.

DOI: https://doi.org/10.1182/blood-2021-149112

Published: 2021

Journal Articles

Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients

Blood (2020) 136 (Supplement 1): 26–28.

DOI: https://doi.org/10.1182/blood-2020-142082

Published: 2020

Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Blood (2020) 136 (Supplement 1): 43–45.

DOI: https://doi.org/10.1182/blood-2020-136148

Published: 2020

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Benjamin Diamond, MD, Neha Korde, MD, Alexander M. Lesokhin, MD, Eric L Smith, MDPhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X. Lu, MD PhD, Carlyn Tan, MD, Donna Massey, MSN, RN, Meghan Salcedo, BSN, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Kathryn Ciardiello, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata D Yellapantula, Francesco Maura, MD, Tim J Peterson, PharmD, Andriy Derkach, PhD, Sean Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan L. Shah, MDMS, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2020) 136 (Supplement 1): 18–19.

DOI: https://doi.org/10.1182/blood-2020-140152

Published: 2020

Journal Articles

Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls

Urvi A Shah, MD, Sæmundur Rögnvaldsson, BS, Andriy Derkach, PhD, Magnus Björkholm, MD PhD, Ingemar Turesson, MD PhD, Yael David, PhD, Malin Hultcrantz, MD PhD, Carlyn Tan, MD, Hani Hassoun, MD, Neha Korde, MD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Sigurður Yngvi Kristinsson, MD PhD, Ola Landgren, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

DOI: https://doi.org/10.1182/blood-2020-141597

Published: 2020

Journal Articles

VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup

Carlyn Tan, MD, Benjamin Diamond, MD, Malin Hultcrantz, MD PhD, Neha Korde, MD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X. Lu, MD PhD, Dhwani Patel, MD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Andriy Derkach, PhD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

DOI: https://doi.org/10.1182/blood-2020-141988

Published: 2020

Journal Articles

A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)

Blood (2020) 136 (Supplement 1): 8–10.

DOI: https://doi.org/10.1182/blood-2020-141131

Published: 2020

Journal Articles

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Elizabeth Hill, MD, Neha Korde, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Ashley Carpenter, RN, Monica Epstein, RN, Crystal Lu, PharmD, BCOP, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD

Blood (2020) 136 (Supplement 1): 11–12.

DOI: https://doi.org/10.1182/blood-2020-136182

Published: 2020

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Hani Hassoun, MD, Carlyn Tan, MD, Urvi A Shah, MD, Sydney X. Lu, MD PhD, Benjamin Diamond, MD, Meghan Salcedo, RN, Kelly Werner, RN, Jenna Rispoli, RN, Julia Caple, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Isabel Concepcion, NP, Ciardello Amanda, MS, Aisara Chansakul, BS, Julia Schlossman, BA, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Angela Harrison, MS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata Yellapantula, PhD, Francesco Maura, MD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Andriy Derkach, PhD, Sergio A. Giralt, MD, Neha Korde, MD

Blood (2020) 136 (Supplement 1): 7.

DOI: https://doi.org/10.1182/blood-2020-142466

Published: 2020

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Blood (2019) 134 (Supplement_1): 862.

DOI: https://doi.org/10.1182/blood-2019-126378

Published: 2019

Journal Articles

Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree

Elizabeth Hill, MD, Neha Korde, MD, Sham Mailankody, MBBS, Candis Morrison, CNP, PhD, Alexander Dew, DO, Jennifer Hsu Albert, RN, Katherine Graap, RN, Francesco Maura, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD

Blood (2019) 134 (Supplement_1): 1794.

DOI: https://doi.org/10.1182/blood-2019-126952

Published: 2019

Journal Articles

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Katrina M Piedra, PharmD, Hani Hassoun, MD, Larry W. Buie, PharmD, BCOP, FASHP, Sean M. Devlin, PhD, Jessica Flynn, BS, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sydney X Lu, MD PhD, Sham Mailankody, MBBS, Urvi A Shah, MD, Eric L Smith, MD PhD, Ola Landgren, MD PhD, Neha Korde, MD, Tim J Peterson, PharmD

Blood (2019) 134 (Supplement_1): 1835.

DOI: https://doi.org/10.1182/blood-2019-124403

Published: 2019

Journal Articles

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Marion Eveillard, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Eric L Smith, MD PhD, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X Lu, MD PhD, Neha Korde, MD, Ola Landgren, MD PhD, Katie Thoren, PhD

Blood (2019) 134 (Supplement_1): 4377.

DOI: https://doi.org/10.1182/blood-2019-128938

Published: 2019

Journal Articles

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Tim J Peterson, PharmD, Neha Korde, MD, Hani Hassoun, MD, Sham Mailankody, MBBS, Alexander M. Lesokhin, MD, Malin Hultcrantz, MD PhD, Urvi A Shah, MD, Eric L Smith, MD PhD, Sydney X Lu, MD PhD, Heather J Landau, MD, Gunjan L. Shah, MD, Michael Scordo, MD, Oscar B Lahoud, MD, Sergio A Giralt, MD, Ola Landgren, MD PhD

Blood (2019) 134 (Supplement_1): 5554.

DOI: https://doi.org/10.1182/blood-2019-124376

Published: 2019

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Donna Mastey, RN, Alexander M. Lesokhin, MD, Eric L Smith, MD PhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X Lu, MD PhD, Meghan Salcedo, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Ciardiello, BS, Elizabeth Tavitian, BS, Tala Shekarkhand, BS, Even Rustad, MD, Venkata Yellapantula, PhD, Francesco Maura, MD, Tim J Peterson, PharmD, Sean M. Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, PhD, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio Giralt, MD, Neha Korde, MD

Blood (2019) 134 (Supplement_1): 3127.

DOI: https://doi.org/10.1182/blood-2019-125842

Published: 2019

2 3 4

NARROW

A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study

Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd)

Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls

A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only